By Gina Shaw
Hospitals in the federal 340B Drug Pricing Program reacted with dismay to the May 18 announcement that the Department of Health and Human Services would yet again delay the enforcement of a regulation that would prevent drug companies from overcharging hospitals in the program.
In 2010, Congress mandated that HHS set drug price ceilings for the 340B program and establish civil monetary penalties when manufacturers “knowingly and intentionally overcharge 340B covered